Wexford Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Wexford Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,485	Closed	-$37K	–	381
2020 Q4	$37K	Buy	+1,485	New	+$49.2K	0.01%	281
2017 Q3	–	Sell	-2,800	Closed	-$339K	–	202
2017 Q2	$339K	Buy	+2,800	New	+$324K	0.03%	147

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Wexford Capital's ICPT Position: Q1 2021 in Review

Wexford Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2021, closing a stake of 1,485 shares — an estimated $37K sold.

Wexford Capital first reported a position in ICPT in Q2 2017 and held it in 2 quarters. The position peaked at $339K in Q2 2017. 151 funds tracked by Wall St. Rank hold ICPT as of Q1 2021.

Wexford Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 1,485 Intercept Pharmaceuticals, Inc. shares in Q1 2021, an estimated $37K.
Wexford Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
Wexford Capital's Intercept Pharmaceuticals, Inc. position peaked at $339K in Q2 2017.
151 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.